- Home
- EWCZ vs ALDX Comparison
EWCZ vs ALDX Comparison
Compare EWCZ & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWCZ
- ALDX
- Stock Information
- Founded
- EWCZ 2004
- ALDX 2004
- Country
- EWCZ United States
- ALDX United States
- Employees
- EWCZ N/A
- ALDX N/A
- Industry
- EWCZ Package Goods/Cosmetics
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- EWCZ Consumer Discretionary
- ALDX Health Care
- Exchange
- EWCZ Nasdaq
- ALDX Nasdaq
- Market Cap
- EWCZ 239.2M
- ALDX 270.7M
- IPO Year
- EWCZ 2021
- ALDX 2014
- Fundamental
- Price
- EWCZ $4.22
- ALDX $4.81
- Analyst Decision
- EWCZ Buy
- ALDX Strong Buy
- Analyst Count
- EWCZ 7
- ALDX 2
- Target Price
- EWCZ $5.86
- ALDX $9.50
- AVG Volume (30 Days)
- EWCZ 374.4K
- ALDX 1.2M
- Earning Date
- EWCZ 08-13-2025
- ALDX 08-12-2025
- Dividend Yield
- EWCZ N/A
- ALDX N/A
- EPS Growth
- EWCZ N/A
- ALDX N/A
- EPS
- EWCZ 0.21
- ALDX N/A
- Revenue
- EWCZ $216,469,000.00
- ALDX N/A
- Revenue This Year
- EWCZ N/A
- ALDX N/A
- Revenue Next Year
- EWCZ $2.17
- ALDX $29.89
- P/E Ratio
- EWCZ $20.54
- ALDX N/A
- Revenue Growth
- EWCZ N/A
- ALDX N/A
- 52 Week Low
- EWCZ $2.72
- ALDX $1.14
- 52 Week High
- EWCZ $9.45
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- EWCZ 26.95
- ALDX 53.97
- Support Level
- EWCZ $4.56
- ALDX $5.21
- Resistance Level
- EWCZ $5.16
- ALDX $5.35
- Average True Range (ATR)
- EWCZ 0.20
- ALDX 0.33
- MACD
- EWCZ -0.07
- ALDX -0.12
- Stochastic Oscillator
- EWCZ 1.44
- ALDX 40.70
About EWCZ European Wax Center Inc.
European Wax Center Inc is a franchisor and operator of OOH waxing services. Its product sales consist of revenue earned from sales of proprietary wax. Its services include Brazilian Waxing, Brow Waxing, Body Waxing, Facial Waxing, All Waxing Services, Eyebrow Tinting, Laser Hair Removal, Men's Waxing Services and others.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.